02 September 2020 | News
Hitachi will start practical operation of the platform in 2021
Image credit- shutterstock.com
Japanese firm Hitachi, Ltd. has constructed a platform for the integrated management of cell and tracing information throughout the value chain, from cell collection, through production and transport, to the administration of regenerative medicine products through collaborative creation with Alfresa Corporation (Alfresa), pharmaceutical companies, medical institutions, and others.
Hitachi will start practical operation of the platform in 2021 following an operational test and Alfresa will be one of the first users of the platform.
The platform will individually identify and trace samples, throughout the processes of cell collection, transportation, and administration of regenerative medicine products that require strict quality control and information traceability.
It is the first common service infrastructure for regenerative medicine products in Japan that involves all stakeholders throughout the value chain (medical institutions, pharmaceutical/logistics/manufacturing companies).
The platform will eliminate the need for each company to maintain its own management system, reduce the complication of management arising from differences between businesses' systems, and enable unified data management. As a result, it drives prompt, safe and secure execution of business.